Some companies execute a 3-5 year plan and then revert to average returns. Others 'win by winning'—their success creates new opportunities and network effects, turning them into decade-long compounders that investors often sell too early.

Contrary to the instinct to sell a big winner, top fund managers often hold onto their best-performing companies. The initial 10x return is a strong signal of a best-in-class product, team, and market, indicating potential for continued exponential growth rather than a peak.

Mohnish Pabrai argues against trimming winners. He believes that over decades, a truly skilled fund manager should let their best idea run until it dominates the portfolio, potentially reaching 95% concentration. Selling a rare, generational compounder just to rebalance is a critical mistake he calls "desecration of the temple."

Since it's impossible to know upfront which investments will generate outlier returns, the key isn't picking them but holding them. The biggest mistake is 'cutting your flowers to water your weeds'—selling winners to invest in underperformers. You must 'circle the wagons' around your core assets.

The rule for selling a stagnant stock after three years is less relevant for 'wonderful businesses' that constantly create value. Even if the stock price is flat, the underlying value has grown, improving the risk/reward. The rule is more critical for static-value investments where timing is everything.

In contrast to "Raiders" who sell for a quick 20% gain, the most successful "Connoisseurs" achieve outsized returns by letting their winners run. This long-term conviction, while seemingly boring, is where the majority of wealth is created in a portfolio.

Investors often focus on losses, but the biggest financial mistakes come from selling compounding winners like Costco too early. This happens when short-term IRR calculations, heavily dependent on unpredictable exit multiples, overshadow the long-term value of a great business.

Over 58 years, Warren Buffett made ~400 investment decisions, but only 12 truly mattered—a 4% hit rate. The crucial insight is not just buying right, but holding these few exceptional businesses for decades, allowing compounding to work its magic.

For promising venture-stage companies, price sensitivity is a losing strategy. The truly exceptional opportunities attract significant interest, driving up valuations. According to Andreessen, the mistake of omission (passing on a future giant) far outweighs the mistake of overpaying slightly for a winner.